Actio Biosciences raised $66M in Series B funding to enhance drug research targeting rare genetic diseases. The round was led by Regeneron Ventures and Deerfield Management.
Actio Biosciences raised $66M in Series B funding to enhance drug research targeting rare genetic diseases. The round was led by Regeneron Ventures and Deerfield Management.
06/18/25, 11:47 AM
Location
san diegoMoney raised
$66 million
Industry
therapeutics
biotechnology
health care
Round Type
series b
Investors
Euclidean Capital, Droia Ventures, Canaan, Deerfield Management, Regeneron Ventures
Actio Biosciences, a San Diego-based biotechnology startup, announced Wednesday it raised a $66 million Series B financing to support drug research. The company is initially focusing on rare genetic diseases, with broader potential. Actio's advanced program targets Charcot-Marie-Tooth disease and a second program for genetic epilepsy is expected to enter clinical testing soon. The funding round was co-led by Regeneron Ventures and Deerfield Management, with participation from Canaan, Droia Ventures, and Euclidean Capital.
Company Info
Location
san diego, california, united states
Additional Info
Actio Biosciences is leveraging advances in precision medicine to develop new therapeutics that target shared genetics in rare and common diseases—bringing meaningful medicines from one to many. Applying its expertise in genetics, drug discovery and data sciences, Actio seeks to identify programs targeting the underlying cause of disease where biological risk can be minimized to streamline the drug development process and bring forward exceptionally potent and precisely targeted therapeutics. Actio is advancing two lead rare disease programs – ABS-0871 and ABS-1230 – with first-in-class potential for the treatment of Charcot Marie Tooth disease, Type 2C (CMT2C) and a rare genetic epilepsy, respectively. Founded in October 2021, the San Diego-based company is led by experts in genetics and drug development and backed by top healthcare investors.